<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biopolymers</journal-id><journal-id journal-id-type="publisher-id">bip</journal-id><journal-title-group><journal-title>Biopolymers</journal-title></journal-title-group><issn pub-type="ppub">0006-3525</issn><issn pub-type="epub">1097-0282</issn><publisher><publisher-name>Wiley Subscription Services, Inc., A Wiley Company</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">2816359</article-id><article-id pub-id-type="doi">10.1002/bip.21158</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Influence of naturally-occurring 5&#8242;-pyrophosphate-linked substituents on the binding of adenylic inhibitors to ribonuclease a: An X-ray crystallographic study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Holloway</surname><given-names>Daniel E</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chavali</surname><given-names>Gayatri B</given-names></name><xref ref-type="author-notes" rid="fn1">*</xref></contrib><contrib contrib-type="author"><name><surname>Leonidas</surname><given-names>Demetres D</given-names></name><xref ref-type="author-notes" rid="fn2">&#8224;</xref></contrib><contrib contrib-type="author"><name><surname>Baker</surname><given-names>Matthew D</given-names></name><xref ref-type="author-notes" rid="fn3">&#8225;</xref></contrib><contrib contrib-type="author"><name><surname>Acharya</surname><given-names>K Ravi</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Nafie</surname><given-names>Laurence</given-names></name></contrib></contrib-group><aff><institution>Department of Biology and Biochemistry, University of Bath</institution><addr-line>Claverton Down, Bath BA2 7AY, UK</addr-line></aff><author-notes><fn fn-type="present-address" id="fn1"><label>*</label><p>Present address: Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Hills Rd, Cambridge CB2 0XY, UK</p></fn><fn fn-type="present-address" id="fn2"><label>&#8224;</label><p>Present address: Institute of Organic and Pharmaceutical Chemistry, National Hellenic Research Foundation, 48 Vassileos Constantinou Avenue, 11635 Athens, Greece</p></fn><fn fn-type="present-address" id="fn3"><label>&#8225;</label><p>Present address: School of Biosciences, University of Cardiff, Museum Avenue, Cardiff CF10 3US, UK</p></fn><corresp id="cor1"><italic>Correspondence to:</italic> K. Ravi Acharya; e-mail: <email>k.r.acharya@bath.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>03</day><month>2</month><year>2009</year></pub-date><volume>91</volume><issue>12</issue><fpage>995</fpage><lpage>1008</lpage><history><date date-type="received"><day>11</day><month>12</month><year>2008</year></date><date date-type="rev-recd"><day>26</day><month>1</month><year>2009</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#169; 2009 Wiley Periodicals, Inc., A Wiley Company</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.</license-p></license></permissions><abstract><p>Ribonuclease A is the archetype of a functionally diverse superfamily of vertebrate-specific ribonucleases. Inhibitors of its action have potential use in the elucidation of the in vivo roles of these enzymes and in the treatment of pathologies associated therewith. Derivatives of adenosine 5&#8242;-pyrophosphate are the most potent nucleotide-based inhibitors known. Here, we use X-ray crystallography to visualize the binding of four naturally-occurring derivatives that contain 5&#8242;-pyrophosphate-linked extensions. 5&#8242;-ATP binds with the adenine occupying the B<sub>2</sub> subsite in the manner of an RNA substrate but with the &#947;-phosphate at the P<sub>1</sub> subsite. Diadenosine triphosphate (Ap<sub>3</sub>A) binds with the adenine in <italic>syn</italic> conformation, the &#946;-phosphate as the principal P<sub>1</sub> subsite ligand and without order beyond the &#947;-phosphate. NADPH and NADP<sup>+</sup> bind with the adenine stacked against an alternative rotamer of His119, the 2&#8242;-phosphate at the P<sub>1</sub> subsite, and without order beyond the 5&#8242;-&#945;-phosphate. We also present the structure of the complex formed with pyrophosphate ion. The structural data enable existing kinetic data on the binding of these compounds to a variety of ribonucleases to be rationalized and suggest that as the complexity of the 5&#8242;-linked extension increases, the need to avoid unfavorable contacts places limitations on the number of possible binding modes. &#169; 2009 Wiley Periodicals, Inc. Biopolymers 91: 995&#8211;1008, 2009.</p><p>This article was originally published online as an accepted preprint. The &#8220;Published Online&#8221; date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.com</p></abstract><kwd-group><kwd>enzyme inhibitor</kwd><kwd>RNase A</kwd><kwd>angiogenin</kwd><kwd>eosinophil-derived neurotoxin</kwd><kwd>ATP</kwd><kwd>diadenosine polyphosphates</kwd><kwd>NADPH</kwd><kwd>NADP<sup>+</sup></kwd><kwd>pyrophosphate</kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>Bovine pancreatic ribonuclease A (RNase A; EC 3.1.27.5) has long been studied as a model of enzyme structure and function (reviewed by Raines<xref ref-type="bibr" rid="b1">1</xref>). It is now increasingly recognised as the archetype of an intriguing enzyme superfamily whose actions are closely linked to the evolution of vertebrates and which has undergone tremendous diversification.<xref ref-type="bibr" rid="b2">2</xref>&#8211;<xref ref-type="bibr" rid="b5">5</xref> Many members of the superfamily have potent biological activities that are dependent on their enzymatic activity. Among these are the angiogenic and tumor-promoting activities of angiogenin (Ang),<xref ref-type="bibr" rid="b6">6</xref>&#8211;<xref ref-type="bibr" rid="b8">8</xref> the antiviral and neurotoxic activities of eosinophil-derived neurotoxin (EDN)<xref ref-type="bibr" rid="b9">9</xref>,<xref ref-type="bibr" rid="b10">10</xref> and the cytotoxic activities of bovine seminal ribonuclease<xref ref-type="bibr" rid="b11">11</xref> and Onconase.<xref ref-type="bibr" rid="b12">12</xref> The use of site-directed mutagenesis and broad-spectrum inhibitors such as ribonuclease inhibitor (RI) protein<xref ref-type="bibr" rid="b13">13</xref> have been invaluable in establishing the links between biological and enzymatic activities. However, the development of stable, low-molecular weight inhibitors with high specificity remains a priority for the study of individual enzymes in their natural settings. Furthermore, such compounds may lead to agents for the treatment of pathologies associated with ribonuclease action, most notably anti-tumor agents directed at Ang.<xref ref-type="bibr" rid="b8">8</xref></p><p>RNase A superfamily members cleave the P-O5&#8242; bonds of RNA specifically after pyrimidine residues.<xref ref-type="bibr" rid="b14">14</xref> Inhibition of this action with small molecules has focused principally on the central catalytic and substrate-binding region. This is conventionally divided into subsites named P<sub>1</sub>, B<sub>1</sub>, and B<sub>2</sub>, which bind the scissile bond and the heterocyclic bases immediately upstream (a pyrimidine) and downstream (preferentially a purine), respectively.<xref ref-type="bibr" rid="b14">14</xref>,<xref ref-type="bibr" rid="b15">15</xref> One well-established line of attack involves phosphoadenosine-based nucleotides. Such compounds inhibit a variety of ribonucleases including RNase A, EDN, eosinophil cationic protein (ECP), RNase 4, Ang and, in all likelihood, many others.<xref ref-type="bibr" rid="b16">16</xref> The tightest-binding examples reported thus far are chemically-synthesized derivatives of adenosine 5&#8242;-pyrophosphate (ppA); among these, 5&#8242;-diphosphoadenosine 3&#8242;-phosphate (ppA-3&#8242;-p) and its 5&#8242;-phospho 2&#8242;-deoxyuridine derivative (pdUppA-3&#8242;-p) exhibit <italic>K</italic><sub>i</sub> values of 10<sup>&#8722;8</sup>&#8211;10<sup>&#8722;6</sup><italic>M</italic> when binding to RNase A, EDN, or RNase 4.<xref ref-type="bibr" rid="b17">17</xref>,<xref ref-type="bibr" rid="b18">18</xref> This has been matched only by oligo (vinylsulfonic acid), a polyanion that inhibits RNase A with a <italic>K</italic><sub>i</sub> of 0.12 &#956;<italic>M</italic> under similar buffer conditions containing 0.1<italic>M</italic> NaCl.<xref ref-type="bibr" rid="b19">19</xref></p><p>X-ray crystallographic studies of complexes formed between phosphoadenosine-based inhibitors and RNase A,<xref ref-type="bibr" rid="b20">20</xref>&#8211;<xref ref-type="bibr" rid="b22">22</xref> EDN,<xref ref-type="bibr" rid="b23">23</xref>,<xref ref-type="bibr" rid="b24">24</xref> and ECP<xref ref-type="bibr" rid="b25">25</xref> have shown that these compounds bind minimally to the P<sub>1</sub> and B<sub>2</sub> subsites but can also make additional interactions further afield depending on the nature of substitution. Exploration of the more peripheral interactions may lead to the development of inhibitors that are specific to particular ribonuclease homologs. However, these enzyme&#183;inhibitor systems exhibit remarkable conformational complexity and the confidence with which inhibitor improvements can be derived from the existing data is not high. For example, with the RNase A&#183;inhibitor system (which has received most attention thus far; Table <xref ref-type="table" rid="tbl1">I</xref>), a simple RNA-derived compound such as pA-3&#8242;-p binds in the conventional manner observed for oligonucleotide substrate analogues<xref ref-type="bibr" rid="b32">32</xref>&#8211;<xref ref-type="bibr" rid="b35">35</xref> (here designated as Class Ia) but a radically altered mode is observed upon modification of the compound with phosphate groups at the 5&#8242;- and/or 2&#8242;- positions. The two key torsional parameters that characterize this are the rotameric state of His119 (a residue that contributes to both the P<sub>1</sub> and B<sub>2</sub> subsites) and the <italic>N</italic>-glycosidic torsion angle (&#967;) of the nucleotide. These reflect to a large degree the nature of the base-stacking interaction at the B<sub>2</sub> subsite and the region of the inhibitor that occupies the P<sub>1</sub> subsite.
<table-wrap id="tbl1" position="float"><label>Table I</label><caption><p>Categorized Binding of 5&#8242;-Phosphoadenosine-Based Inhibitors to RNase A</p></caption><table-wrap-foot><fn id="tf1-1"><label>a</label><p>For rotamer A, &#967;<sub>1</sub> &#8776; 150&#176; and &#967;<sub>2</sub> &#8776; &#8722;100&#176;; for rotamer B, &#967;<sub>1</sub> &#8776; &#8722;70&#176; and &#967;<sub>2</sub> &#8776; &#8722;60&#176;.<xref ref-type="bibr" rid="b29">29</xref></p></fn><fn id="tf1-2"><label>b</label><p>The <italic>N</italic>-glycosidic torsion angle, &#967; is the rotation about O4&#8242;&#8211;C1&#8242;&#8211;N9&#8211;C4. In RNA, &#967; is usually <italic>anti</italic> (180&#8211;250&#176;) or high-<italic>anti</italic> (above 250&#176;) but rarely <italic>syn</italic> (&lt;120&#176;).<xref ref-type="bibr" rid="b30">30</xref>,<xref ref-type="bibr" rid="b31">31</xref></p></fn><fn id="tf1-3"><label>c</label><p>Letters in parentheses denote alternate ligand conformations.</p></fn></table-wrap-foot></table-wrap>
</p><p>In view of the conformational uncertainties in the binding of adenylic nucleotides, it remains a priority to extend the panel of inhibitor complexes for which structural data is available. It is pertinent that several naturally-occuring nucleotides that possess a ppA moiety are also effective ribonuclease inhibitors.<xref ref-type="bibr" rid="b36">36</xref> These include 5&#8242;-ATP, <italic>P</italic><sup>1</sup>,<italic>P</italic><sup>3</sup>-bis(5&#8242;-adenosyl) triphosphate (Ap<sub>3</sub>A), NADPH, and NADP<sup>+</sup>. We present here the X-ray crystal structures of these compounds in complex with RNase A, along with that of a pyrophosphate ion (PP<sub>i</sub>) complex of the same. They provide new insight into the consequences of a variety of 5&#8242;-linked extensions on the binding of adenylic nucleotides to RNase A and its homologs, and indicate how improved inhibitors might be developed.</p></sec><sec><title>RESULTS</title><sec><title>Structural Overview</title><p>The structures of monoclinic RNase A crystals soaked with 5&#8242;-ATP, Ap<sub>3</sub>A, NADPH, NADP<sup>+</sup>, and PP<sub>i</sub> were obtained at resolutions of 1.7, 2.4, 1.7, 1.7, and 1.8 &#197;, respectively, as summarized in Table <xref ref-type="table" rid="tbl2">II</xref>. This crystal form presents two protein chains (mol A and mol B) in the asymmetric unit,<xref ref-type="bibr" rid="b20">20</xref> and, with the exception of the Ap<sub>3</sub>A complex, which lacks residue LysA1, each of the structures comprises two complete main chains (residues 1&#8211;124). Density for residues 16&#8211;24 and 87&#8211;90 of each chain is consistently poor, as is typical for this crystal form. In Ramachandran plots, 94.2&#8211;96.7% of non-Pro/Gly residues lie in the most-favored regions with only SerB16 falling in a disfavored region. In no case is the main chain topology perturbed significantly by the presence of the ligand; of the 10 protein chains, nine have C<sup>&#945;</sup> traces that deviate by 0.21&#8211;0.25 &#197; (r.m.s.) from the corresponding chain in monoclinic unliganded RNase A (PDB entry 1AFU),<xref ref-type="bibr" rid="b20">20</xref> whereas for chain A of the Ap<sub>3</sub>A complex, the figure is slightly higher at 0.48 &#197; and appears to be a consequence of the relatively low resolution of this structure.
<table-wrap id="tbl2" position="float"><label>Table II</label><caption><p>Crystallographic Statistics</p></caption><table-wrap-foot><fn id="tf2-1"><label>a</label><p><italic>R</italic><sub>symm</sub> = &#931;<sub><italic>h</italic></sub>&#931;<sub><italic>i</italic></sub>[|<italic>I</italic><sub><italic>i</italic></sub>(<italic>h</italic>) &#8722; &#12296;<italic>I</italic>(<italic>h</italic>)&#12297;|/&#931;<sub><italic>h</italic></sub>&#931;<sub><italic>i</italic></sub><italic>I</italic><sub><italic>i</italic></sub>(<italic>h</italic>)], where <italic>I</italic><sub><italic>i</italic></sub> is the <italic>i</italic>th measurement and &#12296;<italic>I</italic>(<italic>h</italic>)&#12297; is the weighted mean of all measurements of <italic>I</italic>(<italic>h</italic>).</p></fn><fn id="tf2-2"><label>b</label><p>Values in parentheses refer to the outermost shell.</p></fn><fn id="tf2-3"><label>c</label><p><italic>R</italic><sub>cryst</sub> = &#931;<sub><italic>h</italic></sub>|<italic>F</italic><sub>o</sub>&#8722;<italic>F</italic><sub>c</sub>|/&#931;<sub><italic>h</italic></sub><italic>F</italic><sub>o</sub>, where <italic>F</italic><sub>o</sub> and <italic>F</italic><sub>c</sub> are the observed and calculated structure factor amplitudes of reflection <italic>h</italic>, respectively.</p></fn><fn id="tf2-4"><label>d</label><p><italic>R</italic><sub>free</sub> is equal to <italic>R</italic><sub>cryst</sub> for a randomly selected 5&#8211;10% of reflections not used in the refinement.<sup>37</sup></p></fn></table-wrap-foot></table-wrap>
</p><p>Chemical structures, harmonized atom nomenclature, and conserved torsion angles of the nucleotide inhibitors are presented in Figure <xref ref-type="fig" rid="fig01">1</xref>. For each of these compounds, the electron density data indicate clearly the position of one adenine ring and 2&#8211;3 phosphate groups but not that of the intervening ribosyl moiety (Figure <xref ref-type="fig" rid="fig02">2</xref>). This parallels the difficulty experienced in locating the ribosyl backbone atoms in many RNA structures.<xref ref-type="bibr" rid="b38">38</xref> Plausible coordinates were derived through crystallographic refinement with REFMAC5<xref ref-type="bibr" rid="b39">39</xref> with referral to the all-atom contact analysis of MolProbity<xref ref-type="bibr" rid="b40">40</xref> and in the knowledge that the lever-actions of the base and phosphates dictate to a large degree the sugar's conformation.<xref ref-type="bibr" rid="b41">41</xref> The position of each of the nucleotide inhibitors is better defined in mol A than in mol B. In several cases, this may be due to the stabilizing influence of a crystal contact, as described in more detail below.
<fig id="fig01" position="float"><label>FIGURE 1</label><caption><p>Chemical structures, harmonized atom numbering, and conserved torsion angles of 5&#8242;-ATP, Ap<sub>3</sub>A, NADPH, and NADP<sup>+</sup>.</p></caption><graphic xlink:href="bip0091-0995-f1"/></fig>
<fig id="fig02" position="float"><label>FIGURE 2</label><caption><p>Electron density maps for the nucleotide inhibitors. Shown in stereo for (a) 5&#8242;-ATP (mol A), (b) Ap<sub>3</sub>A (mol A), (c) NADPH (mol A), (d) NADP<sup>+</sup> (mol A), and (e) PP<sub>i</sub> (mol B) is the ball-and-stick structure of the refined inhibitor (or fragment thereof) superposed with the corresponding portion of the total OMIT map calculated with SFCHECK<xref ref-type="bibr" rid="b62">62</xref> and contoured at 1.3&#963;. The coloring scheme is: carbon, gold; nitrogen, blue; oxygen, red; phosphorus, pink; electron density, green.</p></caption><graphic xlink:href="bip0091-0995-f2"/></fig>
</p></sec><sec><title>Structure of the RNase A&#183;5&#8242;-ATP Complex</title><p>The inhibition of RNase A by simple 5&#8242;-phosphorylated adenosines becomes progressively stronger as the number of phosphates is increased. Under equivalent conditions, <italic>K</italic><sub>i</sub> values for 5&#8242;-AMP (pA), 5&#8242;-ADP (ppA), and 5&#8242;-ATP (pppA) are 80, 1.2, and 0.86 &#956;<italic>M</italic>, respectively.<xref ref-type="bibr" rid="b18">18</xref>,<xref ref-type="bibr" rid="b36">36</xref> The 67-fold drop in <italic>K</italic><sub>i</sub> experienced when moving from 5&#8242;-AMP to 5&#8242;-ADP coincides with a radical change in nucleotide conformation (Class Ia/Ib to Class II; Table <xref ref-type="table" rid="tbl1">I</xref>).<xref ref-type="bibr" rid="b22">22</xref>,<xref ref-type="bibr" rid="b26">26</xref> We now present the crystal structure of the RNase A&#183;5&#8242;-ATP complex. The electron density map indicates the position of the base, the &#946;- and the &#947;-phosphate but there is significant disorder in between (Figure <xref ref-type="fig" rid="fig02">2</xref>a). The adenine ring is positioned as in the 5&#8242;-AMP complex, stacking with His119 (rotamer A) and hydrogen-bonding with Asn71 in a conventional (Class Ia) fashion, but a small decrease in &#967; coupled with a pronounced curvature of the triphosphate chain brings the &#947;- rather than the &#945;-phosphate into the P<sub>1</sub> subsite (Figure <xref ref-type="fig" rid="fig03">3</xref>; Table <xref ref-type="table" rid="tbl3">III</xref>). As such, the binding mode conforms to Class Ib. The two instances of the inhibitor in the asymmetric unit show modest differences in their ribose and triphosphate conformations that permit alternative hydrogen-bonding arrangements. Bonds are consistently made between the &#947;-phosphate and His12, His119, and Phe120 but involve different inhibitor atoms (Table <xref ref-type="table" rid="tbl4">IV</xref>). Also, whereas in mol A there are two potential hydrogen bonds between the &#946;-phosphate and Gln11, in mol B there is one between the &#947;-phosphate and this residue. There are no direct interactions between the inhibitor and symmetry-related protein atoms that might explain the differences, and the underlying cause is not clear. Water-mediated interactions are made with Gln11, Asn67, Val118 (mol A only), Phe120 (mol A only), and Asp121, while Coulombic interactions link the N<sup>&#950;</sup> atom of Lys7 (a component of the P<sub>2</sub> subsite) and the polyphosphate chain, the closest approach being 3.6 &#197; to the &#946;-phosphate in mol A.
<fig id="fig03" position="float"><label>FIGURE 3</label><caption><p>RNase A&#183;5&#8242;-ATP complex (mol A). Shown in stereo are ball-and-stick representations of the inhibitor and RNase A residues in and around the binding site, along with a surface representation of the enzyme. Main chain N, C, and O atoms of residues K7, Q11, H12, K41, V43, and E111 are omitted for clarity. The coloring scheme is: nucleotide carbon, gold; protein carbon, gray; nitrogen, blue; oxygen, red; phosphorus, pink. Spheres denote water molecules and dashed lines denote hydrogen bonds.</p></caption><graphic xlink:href="bip0091-0995-f3"/></fig>
<table-wrap id="tbl3" position="float"><label>Table III</label><caption><p>Conformations of the Nucleotide Inhibitors</p></caption><table-wrap-foot><fn id="tf3-1"><label>a</label><p>Torsion angle definitions follow IUPAC-IUB recommendations<xref ref-type="bibr" rid="b42">42</xref> where possible and are illustrated in part in Figure <xref ref-type="fig" rid="fig01">1</xref>.</p></fn><fn id="tf3-2"><label>b</label><p>Because of rotational permutations, the positions of atom O3A in NADPH/NADP<sup>+</sup> and atom O3G in 5&#8242;-ATP/Ap<sub>3</sub>A are ambiguous. However, they have been assigned as the most solvent-exposed oxygen and included for comparison.</p></fn><fn id="tf3-3"><label>c</label><p>As described by Altona and Sandaralingam.<xref ref-type="bibr" rid="b43">43</xref></p></fn></table-wrap-foot></table-wrap>
<table-wrap id="tbl4" position="float"><label>Table IV</label><caption><p>Potential Hydrogen Bonds Between RNase A and the Nucleotide Inhibitors</p></caption><table-wrap-foot><fn id="tf4-1"><label>a</label><p>Potential hydrogen bonds are listed if identified with HBPLUS<xref ref-type="bibr" rid="b44">44</xref> and corroborated by clear electron density for donor and acceptor.</p></fn><fn id="tf4-2"><label>b</label><p>Crystal contact with symmetry-related mol B.</p></fn><fn id="tf4-3"><label>c</label><p>Distance exceeds normal limits but is included for comparison.</p></fn></table-wrap-foot></table-wrap>
</p><p>5&#8242;-ATP is the first compound containing a &#947;-phosphate group for which the three-dimensional details of RNase A binding have been obtained. Previous studies on adenylic nucleotides that contain a 5&#8242;-pyrophosphate group (in various states of derivatization) are consistent in their description of a <italic>syn</italic> base conformation and in their placement of &#946;-phosphate as the major P<sub>1</sub> subsite ligand when bound to RNase A (Class II binding). The conformation observed here for RNase A-bound 5&#8242;-ATP represents a deviation from this pattern and offers an explanation for the stagnation in <italic>K</italic><sub>i</sub> encountered when moving from 5&#8242;-ADP to 5&#8242;-ATP. That is, although the Class II binding mode can support productive interactions of additional 5&#8242;-&#946;-phosphate-linked substituents (e.g., in the binding of pdUppA-3&#8242;-p),<xref ref-type="bibr" rid="b21">21</xref> with 5&#8242;-ATP these are not as favorable as those involving the &#947;-phosphate after adoption of the <italic>anti</italic> conformation observed here.</p><p>5&#8242;-ATP also inhibits EDN, albeit &#8764;25-fold less effectively (<italic>K</italic><sub>i</sub> = 21 &#956;<italic>M</italic>).<xref ref-type="bibr" rid="b36">36</xref> The manner in which this compound binds to EDN (PDB entry 2C01)<xref ref-type="bibr" rid="b24">24</xref> differs from that observed here with RNase A. A mixture of two conformations is present, neither of which is particularly well ordered. In one of these (conformation A), the adenine ring is bound as in RNase A, but the P<sub>1</sub> subsite is occupied principally by the &#945;-phosphate whereas the &#947;-phosphate is disordered. The catalytic centers of the two proteins are highly similar, and it seems that electronic and/or steric effects of a subtle nature are responsible for the differences in binding. Whatever the case, the superior inhibition of RNase A correlates with a better-defined and more extensive interaction between inhibitor and protein.</p></sec><sec><title>Structure of the RNase A&#183;Ap<sub>3</sub>A Complex</title><p>Extension of 5&#8242;-ATP by attachment of a 5&#8242;-linked adenosine, thereby generating Ap<sub>3</sub>A (Figure <xref ref-type="fig" rid="fig01">1</xref>), causes a 34-fold decrease in affinity (<italic>K</italic><sub>i</sub> = 29 &#956;<italic>M</italic>).<xref ref-type="bibr" rid="b36">36</xref> To find an explanation, we determined the structure of the RNase A&#183;Ap<sub>3</sub>A complex. The electron density map indicates the position of a portion of the nucleotide corresponding to a 5&#8242;-ATP moiety (Figure <xref ref-type="fig" rid="fig02">2</xref>b), and the remainder of the inhibitor is presumed to be in no fixed conformation. The visible portion has the adenine/His119 rotamer A stacking arrangement and <italic>syn</italic> base conformation of the Class II binding mode associated with 5&#8242;-pyrophosphate-containing adenine nucleotides (Figure <xref ref-type="fig" rid="fig04">4</xref>a; Table <xref ref-type="table" rid="tbl3">III</xref>). There are modest differences in the binding of the inhibitor to the two protein chains in the asymmetric unit. These appear to derive from a hydrogen bond in mol A between O2&#8242; of the ribose and O<sup>&#947;1</sup> of a symmetry-related ThrB70 residue. This has negligible impact on the adenine position but alters the conformation of the ribose and, to a lesser degree, the polyphosphate chain (Table <xref ref-type="table" rid="tbl3">III</xref>). Two hydrogen bonds between the adenine and the side chain of Asn71 are maintained, as is one between the &#946;-phosphate and His12, and one between the &#947;-phosphate and Lys41 (Table <xref ref-type="table" rid="tbl4">IV</xref>). The N<sup>&#950;</sup> atom of Lys7 is &#8764; 4 &#197; away from the &#945;-phosphate, close enough for significant Coulombic interactions. Differences between the two instances of the inhibitor include a hydrogen bond between the &#945;-phosphate and His119 in mol A only and one between the &#946;-phosphate and Phe120 in mol B only.
<fig id="fig04" position="float"><label>FIGURE 4</label><caption><p>RNase A&#183;Ap<sub>3</sub>A complex (mol A). (a) Enzyme and inhibitor in the same representation and orientation as in Figure <xref ref-type="fig" rid="fig03">3</xref>. The inhibitor is disordered beyond the 5&#8242;-&#947;-phosphate. (b) Comparison with the EDN&#183;Ap<sub>3</sub>A complex (PDB entry 2C02).<xref ref-type="bibr" rid="b24">24</xref> The two complexes were superposed on the basis of the C<sup>&#945;</sup> positions of key nucleotide-binding residues (from RNase A, mol A: Q11, H12, K41, T45, H119, and F120; from EDN: Q14, H15, K38, T42, H129, and L130). Shown in stereo in the same orientation as in panel a are ball-and-stick representations of RNase A-bound Ap<sub>3</sub>A (colored as in panel a), EDN-bound Ap<sub>3</sub>A (white), and neighboring EDN residues (green), along with a surface representation of EDN. Main chain N, C, and O atoms of residues W10, Q14, H15, K38, Q40, and D112 are omitted for clarity. The EDN-bound inhibitor is disordered beyond the 5&#8242;-&#946;-phosphate.</p></caption><graphic xlink:href="bip0091-0995-f4"/></fig>
</p><p>Although they comprise the same set of atoms, RNase A-bound 5&#8242;-ATP and the ordered portion of likewise-bound Ap<sub>3</sub>A exhibit conformations that are clearly very different from one another. In the 5&#8242;-ATP complex, the compact conformation of the polyphosphate chain and the tendency of the &#947;-phosphate toward burial among the P<sub>1</sub> subsite residues appears to leave little scope for the addition of a second 5&#8242;-linked adenosine (see Figure <xref ref-type="fig" rid="fig03">3</xref>). A switch to the Class II binding mode, however, provides an exit route for the 5&#8242;-extension, as is observed for other inhibitors such as pdUppA-3&#8242;-p.<xref ref-type="bibr" rid="b21">21</xref> The loss of 1&#8211;2 hydrogen bonds that accompanies this change most likely contributes to the decrease in affinity that is observed when moving from 5&#8242;-ATP to Ap<sub>3</sub>A.</p><p>Ap<sub>3</sub>A inhibits EDN with a similar potency (<italic>K</italic><sub>i</sub> = 70 &#956;<italic>M</italic>).<xref ref-type="bibr" rid="b36">36</xref> When bound to EDN (PDB entry 2C02),<xref ref-type="bibr" rid="b24">24</xref> the conformation of the second adenosine moiety is likewise disordered, but a <italic>syn</italic> base conformation is not observed. The reason for this is the need to avoid an overlap between the O3&#8242; edge of the ribose and the side chain of Trp7 (a residue whose counterpart in RNase A is Ala4) (Figure <xref ref-type="fig" rid="fig04">4</xref>b). The &#945;- and &#946;-phosphates appear to hydrogen-bond with EDN's P<sub>1</sub> subsite but it was not possible to arrive at a definitive arrangement due to disorder in the nucleotide.<xref ref-type="bibr" rid="b24">24</xref> It seems likely that hydrogen-bonding is less extensive than in the RNase A complex and that this is compensated for by the adoption of a more favorable base conformation to give a similar binding affinity.</p></sec><sec><title>Structures of the RNase A&#183;NADPH and RNase A&#183;NADP<sup>+</sup> Complexes</title><p>The compound ppA-2&#8242;-p is among the tightest-binding RNase A inhibitors known (<italic>K</italic><sub>i</sub> = 0.52 &#956;<italic>M</italic>).<xref ref-type="bibr" rid="b18">18</xref> NADPH and NADP<sup>+</sup> are naturally-occurring substances that contain a ppA-2&#8242;-p moiety yet are considerably less effective inhibitors with <italic>K</italic><sub>i</sub> values of 12 and 63 &#956;<italic>M</italic>, respectively.<xref ref-type="bibr" rid="b36">36</xref> Seeking an explanation, we determined the crystal structures of NADPH and NADP<sup>+</sup> in complex with RNase A. These reveal no major differences between the binding of the two inhibitors and therefore they will be treated together.</p><p>The electron density map permits modelling of a pA-2&#8242;-p moiety; no density is observed for the 5&#8242;-&#946;-phosphate, nicotinamide or the intervening sugar and they are presumed to be in no fixed conformation (Figures <xref ref-type="fig" rid="fig02">2</xref>c and <xref ref-type="fig" rid="fig02">2</xref>d). The adenine ring stacks against His119 (rotamer B) and the 2&#8242;-phosphate occupies the P<sub>1</sub> subsite (Figure <xref ref-type="fig" rid="fig05">5</xref>). This conforms to Class III binding and matches the mode reported for pA-2&#8242;-p bound to crystalline RNase A (mol A) and EDN or to Ang in solution.<xref ref-type="bibr" rid="b22">22</xref>,<xref ref-type="bibr" rid="b23">23</xref>,<xref ref-type="bibr" rid="b45">45</xref> Again, there are small conformational differences between the binding of the inhibitor to each of the two protein chains in the asymmetric unit. These appear to stem from a hydrogen bond in mol A between adenine atom N6 and atom O<sup>&#947;1</sup> of a symmetry-related ThrB70 residue (the same residue that affects Ap<sub>3</sub>A binding). This brings about a 3.4-&#197; shift in the position of atom N6 and compensatory adjustments to the remainder of the inhibitor (Table <xref ref-type="table" rid="tbl3">III</xref>). However, it has minimal effect on the 2&#8242;-phosphate group, which is particularly well ordered in the electron density map, suggesting that it is the main focal point for binding. The 2&#8242;-phosphate hydrogen-bonds with His12, His119, Phe120, and Gln11 (mol B only) (Figure <xref ref-type="fig" rid="fig05">5</xref>, Table <xref ref-type="table" rid="tbl4">IV</xref>). There are also water-mediated interactions between the inhibitor and Gln11, Lys41, Gln69, Asp121, Val118 (mol A only), and Asn71 (mol B only). The N<sup>&#950;</sup> atom of Lys7 is roughly equidistant from the 2&#8242;- and 5&#8242;-&#945;-phosphate groups; at 5.8&#8211;6.6 &#197; away, it is somewhat more remote than in the other complexes described in this report. The 5&#8242;-&#945;-phosphate makes no hydrogen-bonding interactions with the protein and is oriented toward the solvent, indicating that the nicotinamide nucleotide portion is in a disordered, solvent-exposed state.
<fig id="fig05" position="float"><label>FIGURE 5</label><caption><p>RNase A&#183;NADPH complex (mol A). Shown are enzyme and inhibitor in the same representation and orientation as in Figure <xref ref-type="fig" rid="fig03">3</xref>. The side chains of V43 and E111 are drawn in dual conformation (as fitted to the electron density) whereas the side chain of V118 is omitted for clarity. The inhibitor is disordered beyond the 5&#8242;-&#945;-phosphate.</p></caption><graphic xlink:href="bip0091-0995-f5"/></fig>
</p><p>Given the similarity between the interactions of RNase A (mol A)-bound pA-2&#8242;-p and those of the visible portions of NADPH/NADP<sup>+</sup>, one might expect a correspondence in <italic>K</italic><sub>i</sub> values. The literature contains no inhibition constant for the RNase A&#183;pA-2&#8242;-p interaction, but structural and kinetic data on EDN,<xref ref-type="bibr" rid="b23">23</xref> ECP,<xref ref-type="bibr" rid="b25">25</xref> and Ang<xref ref-type="bibr" rid="b45">45</xref>,<xref ref-type="bibr" rid="b46">46</xref> indicate that it will be in the region of that measured for pA-3&#8242;-p (<italic>K</italic><sub>i</sub> = 4.7 &#956;<italic>M</italic>),<xref ref-type="bibr" rid="b18">18</xref> which is indeed similar to that reported for NADPH. The present data do not provide a structural basis for the 5-fold decrease in affinity that is measured when moving from NADPH to NADP<sup>+</sup>. It seems most likely that this is related to electrostatic repulsion of the cationic pyridinium ring of NADP<sup>+</sup> by the surplus of positive charge in the active site of the enzyme, as suggested previously.<xref ref-type="bibr" rid="b36">36</xref></p><p>Although both NADPH and NADP<sup>+</sup> contain ppA-2&#8242;-p as a structural element, the adenylic portions of these dinucleotides do not adopt the <italic>syn</italic> base (Class II) conformation observed when ppA-2&#8242;-p binds to RNase A in isolation.<xref ref-type="bibr" rid="b20">20</xref> It is possible that the position and orientation observed for the 5&#8242;-&#946;-phosphate group of enzyme-bound ppA-2&#8242;-p leave no room for accommodation of an adjacent ribosyl group. This differs from the corresponding portion of enzyme-bound ppA-3&#8242;-p<sup>20</sup> which has been shown to offer access to additional 5&#8242;-linked substituents, e.g., those in pdUppA-3&#8242;-p.<xref ref-type="bibr" rid="b21">21</xref></p></sec><sec><title>Structure of the RNase A&#183;PP<sub>i</sub> Complex</title><p>A pyrophosphate moiety is an invariant substituent of the most potent nucleotide-based inhibitors identified to date. Even as a free ion, it inhibits RNase A appreciably (<italic>K</italic><sub>i</sub> &#8776; 170 &#956;<italic>M</italic>),<xref ref-type="bibr" rid="b47">47</xref> highlighting its contribution to the affinity of these inhibitors. In the crystal structure of the RNase A&#183;PP<sub>i</sub> complex, electron density for the ion is clear, particularly so in mol B (Figure <xref ref-type="fig" rid="fig02">2</xref>e). Both halves of the ion interact with the protein via multiple direct and water-mediated hydrogen bonds (Figure <xref ref-type="fig" rid="fig06">6</xref>a). There is very little difference between the two instances of the ion in the asymmetric unit. One half of the ion (which we designate the &#945;-phosphate) hydrogen-bonds with Gln11 N<sup>&#603;2</sup>, His12 N<sup>&#603;2</sup>, His119 N<sup>&#948;1</sup>, and Phe120 N and experiences Coulombic attraction to Lys 7 N<sup>&#950;</sup>, which is at a distance of 5.2 &#197;. The other half (the &#946;-phosphate) hydrogen-bonds with Lys41 N<sup>&#950;</sup> and Phe120 O (provided that the relevant PP<sub>i</sub> oxygen is protonated). Water-mediated hydrogen bonds are also made with Gln11 N<sup>&#603;2</sup> (&#945;-phosphate), Val43 O (&#946;-phosphate, mol B only), Thr45 N (&#946;-phosphate), and Val118 O (&#945;-phosphate, mol A only).
<fig id="fig06" position="float"><label>FIGURE 6</label><caption><p>RNase A&#183;PP<sub>i</sub> complex (mol B). (a) Enzyme and inhibitor in the same representation and approximately the same orientation as in Figure <xref ref-type="fig" rid="fig03">3</xref>. (b) Comparison with the Ang&#183;PP<sub>i</sub> complex (PDB entry 1H52).<xref ref-type="bibr" rid="b49">49</xref> The two complexes were superposed on the basis of the C<sup>&#945;</sup> positions of key nucleotide-binding residues (from RNase A, mol B: Q11, H12, K41, T45, H119, and F120; from Ang: Q12, H13, K40, T44, H114, and L115). Shown in stereo from the same viewpoint as for panel a are ball-and-stick representations of RNase A-bound PP<sub>i</sub> (colored as in panel a), Ang-bound PP<sub>i</sub> (white), and neighboring Ang residues (green), along with a surface representation of Ang. Main chain N, C, and O atoms of residues H8, Q12, H13, and K40 are omitted for clarity. Dashed lines denote hydrogen bonds.</p></caption><graphic xlink:href="bip0091-0995-f6"/></fig>
</p><p>The position of the &#945;-phosphate is a good match to that of a conventionally-bound 5&#8242;-&#945;-phosphate such as that present in pA-3&#8242;-p or d(CpA)<xref ref-type="bibr" rid="b22">22</xref>,<xref ref-type="bibr" rid="b34">34</xref> and is an approximate match to that of the 5&#8242;-&#946;-phosphate present in ppA-3&#8242;-p, ppA-2&#8242;-p or 3&#8242;,5&#8242;-pyrophosphate-linked inhibitors such as pdUppA-3&#8242;-p.<xref ref-type="bibr" rid="b20">20</xref>,<xref ref-type="bibr" rid="b21">21</xref> The position of the &#946;-phosphate does not correspond well with that of any phosphate group among known inhibitors. It is closest to that of the 5&#8242;-&#947;-phosphate in the Ap<sub>3</sub>A complex (Figure <xref ref-type="fig" rid="fig04">4</xref>a) but is further toward the B<sub>1</sub> subsite.</p><p>The details of the RNase A&#183;PP<sub>i</sub> structure aid in the interpretation of the nucleotide-binding properties of the homologous ribonuclease, Ang. Inhibitors of Ang have potential therapeutic use as anti-cancer drugs (reference<xref ref-type="bibr" rid="b8">8</xref> and others therein) but their binding has proved to be far less amenable to crystallographic study owing to the obstructive position of symmetry-related molecules in all crystal forms identified to date and, in some cases, to the cryptic nature of Ang's B<sub>1</sub> subsite.<xref ref-type="bibr" rid="b48">48</xref> The largest entity that has been observed bound to the active site of Ang is a PP<sub>i</sub> ion.<xref ref-type="bibr" rid="b49">49</xref> This binds in a position that is very similar to that observed in the RNase A&#183;PP<sub>i</sub> complex, with Ang residues Gln12, His13, His114, and Leu115 substituting for RNase A residues Gln11, His12, His119, and Phe120, respectively (Figure <xref ref-type="fig" rid="fig06">6</xref>b). The main difference between the two complexes is the rotameric state of the &#946;-phosphate, which permits a hydrogen bond with Lys41 in RNase A but not with its counterpart (Lys40) in Ang. The most likely cause is the need to avert a clash with the C<sup>&#947;</sup> atom of Gln117 (a component of the novel C-terminal segment of Ang) which, when superposed, is located &#8764; 2.5 &#197; from the position occupied by one of the &#946;-phosphate oxygens in the RNase A complex. The loss of this hydrogen bond may contribute to the lower affinity of PP<sub>i</sub> for Ang (<italic>K</italic><sub>i</sub> = 1.7 m<italic>M</italic>).<xref ref-type="bibr" rid="b49">49</xref></p></sec></sec><sec><title>DISCUSSION</title><sec><title>Use of Monoclinic RNase A Crystals in the Study of Inhibitor Binding</title><p>Since their discovery,<xref ref-type="bibr" rid="b20">20</xref> monoclinic RNase A crystals have proven to be well suited to the study and development of ribonuclease inhibitors. In their favor, they grow at low ionic strength and moderate acidity, both of which are conducive to nucleotide binding.<xref ref-type="bibr" rid="b16">16</xref> They also offer good access to the whole B<sub>1</sub>-P<sub>1</sub>-B<sub>2</sub> region of each of the protein molecules in the asymmetric unit, as indicated by the excellent electron density observed for enzyme-bound pdUppA-3&#8242;-p.<xref ref-type="bibr" rid="b21">21</xref> The quality of the present structures supports the utility of these crystals but reaffirms one drawback, namely the potential impact of symmetry-related protein chains on the binding of inhibitors to the B<sub>2</sub> subsite. Mol A is the most affected owing to potential direct hydrogen-bonding interactions between the inhibitor and a symmetry-related ThrB70 residue and, to a lesser degree, to constrainment of GluA111 by its packing against a symmetry-related TyrB115 residue. In addition, GlnA69 and GlnB69 pack against one another, which could conceivably constrain either residue. These features do not affect the overall binding mode or conformational order of the present inhibitors but they have been seen to do so, for example in the binding of pA-2&#8242;-p and dUppA.<xref ref-type="bibr" rid="b22">22</xref>,<xref ref-type="bibr" rid="b27">27</xref> In those cases where there is a degree of conformational disorder and an ensemble of inhibitor conformations exists (e.g., the binding of Ap<sub>3</sub>A, NADPH or NADP<sup>+</sup>), the symmetry-related contacts of mol A might be viewed as a helpful means of selecting a representative conformation, but it may be that mol B is a more reliable indicator of solution behavior.</p></sec><sec><title>Prospects for Improved Adenylic Inhibitors of RNase A</title><p>The conformational diversity of RNase A-bound adenylic inhibitors continues to expand. With our report of the RNase A&#183;5&#8242;-ATP structure, there are now accounts of the binding of 5&#8242;-&#945;-, 5&#8242;-&#946;-, 5&#8242;-&#947;-, and 2&#8242;-phosphates to the P<sub>1</sub> subsite. The torsional flexibility of the nucleotides and the adaptability of the B<sub>2</sub> subsite are key factors. Despite the array of possible conformations, the larger inhibitors investigated here (Ap<sub>3</sub>A, NADPH, and NADP<sup>+</sup>) are only partially visible in their respective electron density maps. The possibility of nonenzymatic cleavage of these inhibitors must be considered. Ap<sub>3</sub>A is known to be susceptible to hydrolytic cleavage within the polyphosphate chain but the reaction yields products (5&#8242;-ADP and 5&#8242;-AMP) that are smaller than the visible moiety (5&#8242;-ATP) and occurs at an insignificant rate (<italic>t</italic><sub>&#189;</sub> = 154 d at 60&#176;C, pH 6.0, and <italic>I</italic> = 0.1).<xref ref-type="bibr" rid="b50">50</xref> For pyridine nucleotides under mildly acidic conditions, polyphosphate cleavage is not a significant form of degradation. It does occur with oxidized forms such as NADP<sup>+</sup> but elevated temperatures and alkaline conditions are required for the detection of products.<xref ref-type="bibr" rid="b51">51</xref>,<xref ref-type="bibr" rid="b52">52</xref> In view of this, the partial electron density observed in the present complexes most likely reflects a lack of interaction between one half of the dinucleotide and the protein. It appears that, as the complexity of the 5&#8242;-linked extension increases, the need to avoid unfavorable protein&#183;inhibitor contacts becomes an overiding influence on the binding mode and a reduced number of modes can support the binding of the compound.</p><p>The incomplete interaction of Ap<sub>3</sub>A, NADPH, and NADP<sup>+</sup> with RNase A is reminiscent of the binding of Ap<sub>3</sub>A and Ap<sub>4</sub>A to EDN.<xref ref-type="bibr" rid="b24">24</xref> With the latter enzyme, further extension of the polyphosphate linker to form Ap<sub>5</sub>A brought about a far more extensive interaction, indicating that inclusion of an appropriate linker can have a dramatic effect on binding. Hence, it remains possible that the decreases in the <italic>K</italic><sub>i</sub> for RNase A inhibition encountered when moving from Ap<sub>3</sub>A (<italic>K</italic><sub>i</sub> = 29 &#956;<italic>M</italic>) through Ap<sub>4</sub>A (<italic>K</italic><sub>i</sub> = 2.6 &#956;<italic>M</italic>) to Ap<sub>5</sub>A (<italic>K</italic><sub>i</sub> = 0.23 &#956;<italic>M</italic>) reflect the formation of new interactions permitted by linker extension, as previously suggested.<xref ref-type="bibr" rid="b36">36</xref></p><p>The details of the NADPH and NADP<sup>+</sup> complexes give insight into the suitability of pA-2&#8242;-p or ppA-2&#8242;-p as a core for the development of larger inhibitors of RNase A. Although three different binding modes have been observed for 2&#8242;-phosphoadenosine-based nucleotides (Table <xref ref-type="table" rid="tbl1">I</xref>), none of these permits binding of the nicotinamide portion of the present nucleotides. As with the diadenosine polyphosphates, the inclusion of extended, unbranched linkers may be necessary to facilitate additional interactions beyond the 5&#8242;-&#946;-phosphate.</p></sec><sec><title>Inhibitors of Specific Ribonuclease Subclasses</title><p>The development of inhibitors that are specific for individual ribonuclease subclasses would be of great value to the study of these enzymes in vivo and for the development of potential ribonuclease-directed therapeutics. High-throughput screening has identified several non-nucleotide inhibitors that bind slightly more tightly to Ang than to RNase A.<xref ref-type="bibr" rid="b53">53</xref> Existing adenylic inhibitors, on the other hand, tend to select against Ang, for which they exhibit <italic>K</italic><sub>i</sub> values that are 2&#8211;3 orders of magnitude greater than those obtained for RNase A.<xref ref-type="bibr" rid="b16">16</xref> With the nucleotides, the design process has been hampered by an inability to obtain Ang&#183;inhibitor complexes in crystalline form and it has been necessary to extrapolate from data on RNase A and other enzymes. To help test the validity of these measures, a direct comparison can now be made between the RNase A&#183;PP<sub>i</sub> and Ang&#183;PP<sub>i</sub> structures.<xref ref-type="bibr" rid="b49">49</xref> It is clear that the manner in which PP<sub>i</sub> binds to RNase A is not an accurate indicator of what occurs when the same group is O5&#8242;-linked to an adenylic nucleotide. The same is true for Ang, as can be deduced from heteronuclear NMR data on its interaction with ppA-2&#8242;-p and dUppA-2&#8242;-p.<xref ref-type="bibr" rid="b45">45</xref> Although there is a close correspondence in the ligand position in the RNase A&#183;PP<sub>i</sub> and Ang&#183;PP<sub>i</sub> structures, there is a difference in the manner in which the two enzymes bind ppA-2&#8242;-p (Class II and Class III modes, respectively). Nevertheless, with the larger derivatives that have been examined (NADPH/NADP<sup>+</sup> with RNase A and dUppA-2&#8242;-p with Ang), the Class III mode prevails (as does the nonengagement of the second nucleotide), suggesting that similar strategies may be necessary to improve the affinity of 2&#8242;-phosphoadenosine-based nucleotides for these enzymes.</p><p>It has been suggested that side chain differences located toward the N-terminus of the protein could contribute to differences in the affinity of adenylic inhibitors for various ribonucleases.<xref ref-type="bibr" rid="b17">17</xref> The contrast between the RNase A&#183;Ap<sub>3</sub>A and EDN&#183;Ap<sub>3</sub>A structures supports this view (Figure <xref ref-type="fig" rid="fig04">4</xref>b). The complete conformational switch that is apparently triggered by the Trp7 side chain of EDN highlights that such steric effects can be strong and could be exploited in the inhibitor design process. In particular, the close proximity of Trp7 to the ribosyl O3&#8242; atom of the inhibitor suggests that O3&#8242;-linked substituents above a certain size may not be tolerated well by this enzyme and may disfavor binding.</p></sec></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Crystallization and Data Collection</title><p>RNase A and the sodium salts of 5&#8242;-ATP, Ap<sub>3</sub>A, NADPH, NADP<sup>+</sup>, and PP<sub>i</sub> were obtained from Sigma and dissolved in water. RNase A crystals were grown at 16&#176;C by the hanging-drop/vapor-diffusion method as described previously.<xref ref-type="bibr" rid="b20">20</xref> These were transferred to a stabilizing solution (25% PEG 4000, 0.02<italic>M</italic> sodium citrate buffer, pH 5.5) supplemented with either 100 m<italic>M</italic> 5&#8242;-ATP, 100 m<italic>M</italic> Ap<sub>3</sub>A, 20 m<italic>M</italic> NADPH, 20 m<italic>M</italic> NADP<sup>+</sup>, or 100 m<italic>M</italic> PP<sub>i</sub> at 16&#176;C for 24 h. Diffraction data were collected at 100 K; for crystals soaked in 5&#8242;-ATP, NADPH, NADP<sup>+</sup>, and PP<sub>i</sub>, this was carried out on stations 14.1, 9.6, 9.6, and 14.2 of the SRS, Daresbury, UK, respectively, whereas for crystals soaked in Ap<sub>3</sub>A, this was conducted in-house using a MAR Research 30-cm image plate mounted on a Rigaku RU-H3R Cu <italic>K</italic>&#945; radiation source. All data were processed using the HKL suite<xref ref-type="bibr" rid="b54">54</xref> and TRUNCATE.<xref ref-type="bibr" rid="b55">55</xref>,<xref ref-type="bibr" rid="b56">56</xref> Detailed data processing statistics are given in Table <xref ref-type="table" rid="tbl2">II</xref>.</p></sec><sec><title>Phase Determination and Refinement</title><p>Initial phases were determined using the molecular replacement routines of AMoRe<xref ref-type="bibr" rid="b57">57</xref> with reference to coordinates of unliganded RNase A obtained previously under the same crystal growth conditions (PDB entry 1AFU).<xref ref-type="bibr" rid="b20">20</xref> Refinement was conducted initially using the rigid-body, simulated annealing, coordinate minimization, and <italic>B</italic>-factor refinement elements of CNS<xref ref-type="bibr" rid="b58">58</xref> and latterly using the maximum-likelihood routines of REFMAC5.<xref ref-type="bibr" rid="b39">39</xref> Throughout, 5&#8211;10% of reflections (depending on resolution) were set aside for cross-validation.<xref ref-type="bibr" rid="b37">37</xref> After every refinement cycle, electron density maps were calculated and used to guide manual adjustments made with either O or COOT.<xref ref-type="bibr" rid="b59">59</xref>,<xref ref-type="bibr" rid="b60">60</xref> Ligands or fragments thereof were introduced on the basis of m<italic>F</italic><sub>o</sub>-D<italic>F</italic><sub>c</sub> maps and refined using geometrical restraints provided by the CCP4 monomer library.<xref ref-type="bibr" rid="b61">61</xref> Water molecules were added at positions where m<italic>F</italic><sub>o</sub>-D<italic>F</italic><sub>c</sub> electron density peak heights exceeded 3&#963; and where potential hydrogen bonds could be made. Model validation was conducted with MolProbity.<xref ref-type="bibr" rid="b40">40</xref> Detailed statistics for each model are given in Table <xref ref-type="table" rid="tbl2">II</xref>.</p><p>Data Deposition: The coordinates and structure factors of RNase A in complex with 5&#8242;-ATP, Ap<sub>3</sub>A, NADPH, NADP<sup>+</sup>, and PP<sub>i</sub> have been deposited in the Protein Data Bank under accession numbers 2W5G, 2W5I, 2W5K, 2W5L, and 2W5M, respectively.</p></sec></sec></body><back><ack><p>The authors thank the staff at SRS Daresbury and Drs Jawahar Swaminathan and Ramanathan Natesh for their assistance with data collection and archiving, and the Royal Society (UK) for an Industry Fellowship to K.R.A.</p></ack><ref-list><title>REFERENCES</title><ref id="b1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raines</surname><given-names>RT</given-names></name></person-group><source>Chem Rev</source><year>1998</year><volume>98</volume><fpage>1045</fpage><lpage>1065</lpage><pub-id pub-id-type="pmid">11848924</pub-id></element-citation></ref><ref id="b2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Beintema</surname><given-names>JJ</given-names></name><name><surname>Breukelman</surname><given-names>HJ</given-names></name><name><surname>Carsana</surname><given-names>A</given-names></name><name><surname>Furia</surname><given-names>A</given-names></name></person-group><person-group person-group-type="editor"><name><surname>D'Alessio</surname><given-names>G</given-names></name><name><surname>Riordan</surname><given-names>JF</given-names></name></person-group><source>Ribonucleases: Structures and Functions</source><year>1997</year><publisher-loc>New York</publisher-loc><publisher-name>Academic Press</publisher-name><fpage>245</fpage><lpage>269</lpage></element-citation></ref><ref id="b3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>S</given-names></name><name><surname>Beintema</surname><given-names>JJ</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><source>Genomics</source><year>2005</year><volume>85</volume><fpage>208</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">15676279</pub-id></element-citation></ref><ref id="b4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pizzo</surname><given-names>E</given-names></name><name><surname>D'Alessio</surname><given-names>G</given-names></name></person-group><source>Gene</source><year>2007</year><volume>406</volume><fpage>8</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">17616268</pub-id></element-citation></ref><ref id="b5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazakou</surname><given-names>K</given-names></name><name><surname>Holloway</surname><given-names>DE</given-names></name><name><surname>Prior</surname><given-names>SH</given-names></name><name><surname>Subramanian</surname><given-names>V</given-names></name><name><surname>Acharya</surname><given-names>KR</given-names></name></person-group><source>J Mol Biol</source><year>2008</year><volume>380</volume><fpage>206</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">18508078</pub-id></element-citation></ref><ref id="b6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>R</given-names></name><name><surname>Vallee</surname><given-names>BL</given-names></name></person-group><source>Biochemistry</source><year>1989</year><volume>28</volume><fpage>7401</fpage><lpage>7408</lpage><pub-id pub-id-type="pmid">2479414</pub-id></element-citation></ref><ref id="b7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curran</surname><given-names>TP</given-names></name><name><surname>Shapiro</surname><given-names>R</given-names></name><name><surname>Riordan</surname><given-names>JF</given-names></name></person-group><source>Biochemistry</source><year>1993</year><volume>32</volume><fpage>2307</fpage><lpage>2313</lpage><pub-id pub-id-type="pmid">8095159</pub-id></element-citation></ref><ref id="b8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>RYT</given-names></name><name><surname>Jenkins</surname><given-names>JL</given-names></name><name><surname>Olson</surname><given-names>KA</given-names></name><name><surname>Key</surname><given-names>ME</given-names></name><name><surname>Fett</surname><given-names>JW</given-names></name><name><surname>Shapiro</surname><given-names>R</given-names></name></person-group><source>Proc Natl Acad Sci USA</source><year>2002</year><volume>99</volume><fpage>10066</fpage><lpage>10071</lpage><pub-id pub-id-type="pmid">12118120</pub-id></element-citation></ref><ref id="b9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>HF</given-names></name><name><surname>Domachowske</surname><given-names>JB</given-names></name></person-group><source>J Leukoc Biol</source><year>2001</year><volume>70</volume><fpage>691</fpage><lpage>698</lpage><pub-id pub-id-type="pmid">11698487</pub-id></element-citation></ref><ref id="b10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorrentino</surname><given-names>S</given-names></name><name><surname>Glitz</surname><given-names>DG</given-names></name><name><surname>Hamann</surname><given-names>KJ</given-names></name><name><surname>Loegering</surname><given-names>DA</given-names></name><name><surname>Checkel</surname><given-names>JL</given-names></name><name><surname>Gleich</surname><given-names>GJ</given-names></name></person-group><source>J Biol Chem</source><year>1992</year><volume>267</volume><fpage>14859</fpage><lpage>14865</lpage><pub-id pub-id-type="pmid">1634526</pub-id></element-citation></ref><ref id="b11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J-S</given-names></name><name><surname>Sou&#269;ek</surname><given-names>J</given-names></name><name><surname>Matou&#353;ek</surname><given-names>J</given-names></name><name><surname>Raines</surname><given-names>RT</given-names></name></person-group><source>Biochem J</source><year>1995</year><fpage>308</fpage></element-citation></ref><ref id="b12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Raines</surname><given-names>RT</given-names></name></person-group><source>Biochemistry</source><year>2003</year><volume>42</volume><fpage>11443</fpage><lpage>11450</lpage><pub-id pub-id-type="pmid">14516195</pub-id></element-citation></ref><ref id="b13"><label>13</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hofsteenge</surname><given-names>J</given-names></name></person-group><person-group person-group-type="editor"><name><surname>D'Alessio</surname><given-names>G</given-names></name><name><surname>Riordan</surname><given-names>JF</given-names></name></person-group><source>Ribonucleases: Structures and Functions</source><year>1997</year><publisher-loc>New York</publisher-loc><publisher-name>Academic Press</publisher-name><fpage>621</fpage><lpage>658</lpage></element-citation></ref><ref id="b14"><label>14</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>FM</given-names></name><name><surname>Wyckoff</surname><given-names>HW</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Boyer</surname><given-names>PD</given-names></name></person-group><source>The Enzymes</source><year>1971</year><publisher-loc>New York</publisher-loc><publisher-name>Academic Press</publisher-name><fpage>647</fpage><lpage>806</lpage></element-citation></ref><ref id="b15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Par&#233;s</surname><given-names>X</given-names></name><name><surname>Nogu&#233;s</surname><given-names>MV</given-names></name><name><surname>de Llorens</surname><given-names>R</given-names></name><name><surname>Cuchillo</surname><given-names>CM</given-names></name></person-group><source>Essays Biochem</source><year>1991</year><volume>26</volume><fpage>89</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">1778187</pub-id></element-citation></ref><ref id="b16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>A</given-names></name><name><surname>Acharya</surname><given-names>KR</given-names></name><name><surname>Shapiro</surname><given-names>R</given-names></name></person-group><source>Methods Enzymol</source><year>2001</year><volume>341</volume><fpage>629</fpage><lpage>648</lpage><pub-id pub-id-type="pmid">11582810</pub-id></element-citation></ref><ref id="b17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>N</given-names></name><name><surname>Shapiro</surname><given-names>R</given-names></name></person-group><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>14902</fpage><lpage>14908</lpage><pub-id pub-id-type="pmid">10329690</pub-id></element-citation></ref><ref id="b18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>N</given-names></name><name><surname>Shapiro</surname><given-names>R</given-names></name><name><surname>Vallee</surname><given-names>BL</given-names></name></person-group><source>Biochem Biophys Res Commun</source><year>1997</year><volume>231</volume><fpage>671</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">9070868</pub-id></element-citation></ref><ref id="b19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>BD</given-names></name><name><surname>Soellner</surname><given-names>MB</given-names></name><name><surname>Raines</surname><given-names>RT</given-names></name></person-group><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>20934</fpage><lpage>20938</lpage><pub-id pub-id-type="pmid">12649287</pub-id></element-citation></ref><ref id="b20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonidas</surname><given-names>DD</given-names></name><name><surname>Shapiro</surname><given-names>R</given-names></name><name><surname>Irons</surname><given-names>LI</given-names></name><name><surname>Russo</surname><given-names>N</given-names></name><name><surname>Acharya</surname><given-names>KR</given-names></name></person-group><source>Biochemistry</source><year>1997</year><volume>36</volume><fpage>5578</fpage><lpage>5588</lpage><pub-id pub-id-type="pmid">9154942</pub-id></element-citation></ref><ref id="b21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonidas</surname><given-names>DD</given-names></name><name><surname>Shapiro</surname><given-names>R</given-names></name><name><surname>Irons</surname><given-names>LI</given-names></name><name><surname>Russo</surname><given-names>N</given-names></name><name><surname>Acharya</surname><given-names>KR</given-names></name></person-group><source>Biochemistry</source><year>1999</year><volume>38</volume><fpage>10287</fpage><lpage>10297</lpage><pub-id pub-id-type="pmid">10441122</pub-id></element-citation></ref><ref id="b22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonidas</surname><given-names>DD</given-names></name><name><surname>Chavali</surname><given-names>GB</given-names></name><name><surname>Oikonomakos</surname><given-names>NG</given-names></name><name><surname>Chrysina</surname><given-names>ED</given-names></name><name><surname>Kosmopoulou</surname><given-names>MN</given-names></name><name><surname>Vlassi</surname><given-names>M</given-names></name><name><surname>Franking</surname><given-names>C</given-names></name><name><surname>Acharya</surname><given-names>KR</given-names></name></person-group><source>Protein Sci</source><year>2003</year><volume>12</volume><fpage>2559</fpage><lpage>2574</lpage><pub-id pub-id-type="pmid">14573867</pub-id></element-citation></ref><ref id="b23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonidas</surname><given-names>DD</given-names></name><name><surname>Boix</surname><given-names>E</given-names></name><name><surname>Prill</surname><given-names>R</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Turton</surname><given-names>R</given-names></name><name><surname>Minson</surname><given-names>K</given-names></name><name><surname>Swaminathan</surname><given-names>GJ</given-names></name><name><surname>Youle</surname><given-names>RJ</given-names></name><name><surname>Acharya</surname><given-names>KR</given-names></name></person-group><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>15009</fpage><lpage>15017</lpage><pub-id pub-id-type="pmid">11154698</pub-id></element-citation></ref><ref id="b24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>MD</given-names></name><name><surname>Holloway</surname><given-names>DE</given-names></name><name><surname>Swaminathan</surname><given-names>GJ</given-names></name><name><surname>Acharya</surname><given-names>KR</given-names></name></person-group><source>Biochemistry</source><year>2006</year><volume>45</volume><fpage>416</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">16401072</pub-id></element-citation></ref><ref id="b25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohan</surname><given-names>CG</given-names></name><name><surname>Boix</surname><given-names>E</given-names></name><name><surname>Evans</surname><given-names>HR</given-names></name><name><surname>Nikolovski</surname><given-names>Z</given-names></name><name><surname>Nogu&#233;s</surname><given-names>MV</given-names></name><name><surname>Cuchillo</surname><given-names>CM</given-names></name><name><surname>Acharya</surname><given-names>KR</given-names></name></person-group><source>Biochemistry</source><year>2002</year><volume>41</volume><fpage>12100</fpage><lpage>12106</lpage><pub-id pub-id-type="pmid">12356310</pub-id></element-citation></ref><ref id="b26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatzopoulos</surname><given-names>GN</given-names></name><name><surname>Leonidas</surname><given-names>DD</given-names></name><name><surname>Kardakaris</surname><given-names>R</given-names></name><name><surname>Kobe</surname><given-names>J</given-names></name><name><surname>Oikonomakos</surname><given-names>NG</given-names></name></person-group><source>FEBS J</source><year>2005</year><volume>272</volume><fpage>3988</fpage><lpage>4001</lpage><pub-id pub-id-type="pmid">16045769</pub-id></element-citation></ref><ref id="b27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jardine</surname><given-names>AM</given-names></name><name><surname>Leonidas</surname><given-names>DD</given-names></name><name><surname>Jenkins</surname><given-names>JL</given-names></name><name><surname>Park</surname><given-names>C</given-names></name><name><surname>Raines</surname><given-names>RT</given-names></name><name><surname>Acharya</surname><given-names>KR</given-names></name><name><surname>Shapiro</surname><given-names>R</given-names></name></person-group><source>Biochemistry</source><year>2001</year><volume>40</volume><fpage>10262</fpage><lpage>10272</lpage><pub-id pub-id-type="pmid">11513604</pub-id></element-citation></ref><ref id="b28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beach</surname><given-names>H</given-names></name><name><surname>Cole</surname><given-names>R</given-names></name><name><surname>Gill</surname><given-names>ML</given-names></name><name><surname>Loria</surname><given-names>JP</given-names></name></person-group><source>J Am Chem Soc</source><year>2005</year><volume>127</volume><fpage>9167</fpage><lpage>9176</lpage><pub-id pub-id-type="pmid">15969595</pub-id></element-citation></ref><ref id="b29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borkakoti</surname><given-names>N</given-names></name><name><surname>Moss</surname><given-names>DM</given-names></name><name><surname>Palmer</surname><given-names>RA</given-names></name></person-group><source>Acta Crystallogr Sect B</source><year>1982</year><fpage>2210</fpage><lpage>2217</lpage></element-citation></ref><ref id="b30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Schneider</surname><given-names>B</given-names></name><name><surname>Murray</surname><given-names>LW</given-names></name><name><surname>Kapral</surname><given-names>GJ</given-names></name><name><surname>Immormino</surname><given-names>RM</given-names></name><name><surname>Headd</surname><given-names>JJ</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name><name><surname>Ham</surname><given-names>D</given-names></name><name><surname>Hershkovits</surname><given-names>E</given-names></name><name><surname>Williams</surname><given-names>LD</given-names></name><name><surname>Keating</surname><given-names>KS</given-names></name><name><surname>Pyle</surname><given-names>AM</given-names></name><name><surname>Micallef</surname><given-names>D</given-names></name><name><surname>Westbrook</surname><given-names>J</given-names></name><name><surname>Berman</surname><given-names>HM</given-names></name></person-group><source>RNA J</source><year>2008</year><volume>14</volume><fpage>465</fpage><lpage>481</lpage></element-citation></ref><ref id="b31"><label>31</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Saenger</surname><given-names>W</given-names></name></person-group><source>Principles of Nucleic Acid Structure</source><year>1984</year><publisher-loc>New York</publisher-loc><publisher-name>Springer-Verlag</publisher-name></element-citation></ref><ref id="b32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontecilla-Camps</surname><given-names>JC</given-names></name><name><surname>de Llorens</surname><given-names>R</given-names></name><name><surname>le Du</surname><given-names>MH</given-names></name><name><surname>Cuchillo</surname><given-names>CM</given-names></name></person-group><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>21526</fpage><lpage>21531</lpage><pub-id pub-id-type="pmid">8063789</pub-id></element-citation></ref><ref id="b33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilliland</surname><given-names>GL</given-names></name><name><surname>Dill</surname><given-names>J</given-names></name><name><surname>Pechik</surname><given-names>I</given-names></name><name><surname>Svensson</surname><given-names>LA</given-names></name><name><surname>Sjolin</surname><given-names>L</given-names></name></person-group><source>Protein Pept Lett</source><year>1994</year><volume>1</volume><fpage>60</fpage><lpage>65</lpage></element-citation></ref><ref id="b34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zegers</surname><given-names>I</given-names></name><name><surname>Maes</surname><given-names>D</given-names></name><name><surname>Dao-Thi</surname><given-names>M-H</given-names></name><name><surname>Poortmans</surname><given-names>F</given-names></name><name><surname>Palmer</surname><given-names>R</given-names></name><name><surname>Wyns</surname><given-names>L</given-names></name></person-group><source>Protein Sci</source><year>1994</year><volume>3</volume><fpage>2322</fpage><lpage>2339</lpage><pub-id pub-id-type="pmid">7756988</pub-id></element-citation></ref><ref id="b35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toiron</surname><given-names>C</given-names></name><name><surname>Gonzalez</surname><given-names>C</given-names></name><name><surname>Bruix</surname><given-names>M</given-names></name><name><surname>Rico</surname><given-names>M</given-names></name></person-group><source>Protein Sci</source><year>1996</year><volume>5</volume><fpage>1633</fpage><lpage>1647</lpage><pub-id pub-id-type="pmid">8844852</pub-id></element-citation></ref><ref id="b36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>K</given-names></name><name><surname>Jenkins</surname><given-names>JL</given-names></name><name><surname>Jardine</surname><given-names>AM</given-names></name><name><surname>Shapiro</surname><given-names>R</given-names></name></person-group><source>Biochem Biophys Res Commun</source><year>2003</year><volume>300</volume><fpage>81</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">12480524</pub-id></element-citation></ref><ref id="b37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Br&#252;nger</surname><given-names>AT</given-names></name></person-group><source>Nature</source><year>1992</year><volume>355</volume><fpage>472</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">18481394</pub-id></element-citation></ref><ref id="b38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>LJW</given-names></name><name><surname>Arendall</surname><given-names>WB</given-names><suffix>III</suffix></name><name><surname>Richardson</surname><given-names>DC</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name></person-group><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>13904</fpage><lpage>13909</lpage><pub-id pub-id-type="pmid">14612579</pub-id></element-citation></ref><ref id="b39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murshudov</surname><given-names>GN</given-names></name><name><surname>Vagin</surname><given-names>AA</given-names></name><name><surname>Dodson</surname><given-names>EJ</given-names></name></person-group><source>Acta Crystallogr Sect D</source><year>1997</year><volume>53</volume><fpage>240</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">15299926</pub-id></element-citation></ref><ref id="b40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>IW</given-names></name><name><surname>Leaver-Fay</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Block</surname><given-names>JN</given-names></name><name><surname>Kapral</surname><given-names>GJ</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Murray</surname><given-names>LW</given-names></name><name><surname>Arendall</surname><given-names>WB</given-names><suffix>III</suffix></name><name><surname>Snoeyink</surname><given-names>J</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name></person-group><source>Nucleic Acids Res</source><year>2007</year><volume>35</volume><fpage>W375</fpage><lpage>W383</lpage><pub-id pub-id-type="pmid">17452350</pub-id></element-citation></ref><ref id="b41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>PR</given-names></name></person-group><source>Acta Crystallogr Sect D</source><year>2007</year><volume>63</volume><fpage>58</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">17164527</pub-id></element-citation></ref><ref id="b42"><label>42</label><element-citation publication-type="journal"><collab>IUPAC-IUB Joint Commission on Biochemical Nomenclature</collab><source>Eur J Biochem</source><year>1983</year><volume>131</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">6832147</pub-id></element-citation></ref><ref id="b43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altona</surname><given-names>C</given-names></name><name><surname>Sandaralingam</surname><given-names>M</given-names></name></person-group><source>J Am Chem Soc</source><year>1972</year><volume>94</volume><fpage>8205</fpage><lpage>8212</lpage><pub-id pub-id-type="pmid">5079964</pub-id></element-citation></ref><ref id="b44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>IK</given-names></name><name><surname>Thornton</surname><given-names>JM</given-names></name></person-group><source>J Mol Biol</source><year>1994</year><volume>238</volume><fpage>777</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">8182748</pub-id></element-citation></ref><ref id="b45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonan</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Jenkins</surname><given-names>JL</given-names></name><name><surname>Russo</surname><given-names>A</given-names></name><name><surname>Shapiro</surname><given-names>R</given-names></name><name><surname>Ni</surname><given-names>F</given-names></name></person-group><source>Biochemistry</source><year>2003</year><volume>42</volume><fpage>11137</fpage><lpage>11149</lpage><pub-id pub-id-type="pmid">14503864</pub-id></element-citation></ref><ref id="b46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>N</given-names></name><name><surname>Acharya</surname><given-names>KR</given-names></name><name><surname>Vallee</surname><given-names>BL</given-names></name><name><surname>Shapiro</surname><given-names>R</given-names></name></person-group><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><fpage>804</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">8570639</pub-id></element-citation></ref><ref id="b47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>DG</given-names></name><name><surname>Hammes</surname><given-names>GG</given-names></name><name><surname>Walz</surname><given-names>JFG</given-names></name></person-group><source>Biochemistry</source><year>1968</year><volume>7</volume><fpage>1637</fpage><lpage>1644</lpage><pub-id pub-id-type="pmid">4297049</pub-id></element-citation></ref><ref id="b48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acharya</surname><given-names>KR</given-names></name><name><surname>Shapiro</surname><given-names>R</given-names></name><name><surname>Allen</surname><given-names>SC</given-names></name><name><surname>Riordan</surname><given-names>JF</given-names></name><name><surname>Vallee</surname><given-names>BL</given-names></name></person-group><source>Proc Natl Acad Sci USA</source><year>1994</year><volume>91</volume><fpage>2915</fpage><lpage>2919</lpage><pub-id pub-id-type="pmid">8159679</pub-id></element-citation></ref><ref id="b49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonidas</surname><given-names>DD</given-names></name><name><surname>Chavali</surname><given-names>GB</given-names></name><name><surname>Jardine</surname><given-names>AM</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Shapiro</surname><given-names>R</given-names></name><name><surname>Acharya</surname><given-names>KR</given-names></name></person-group><source>Protein Sci</source><year>2001</year><volume>10</volume><fpage>1669</fpage><lpage>1676</lpage><pub-id pub-id-type="pmid">11468363</pub-id></element-citation></ref><ref id="b50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valakoski</surname><given-names>S</given-names></name><name><surname>Heiskanen</surname><given-names>S</given-names></name><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>L&#228;hde</surname><given-names>M</given-names></name><name><surname>Mikkola</surname><given-names>SJ</given-names></name></person-group><source>Chem Soc Perkin Trans</source><year>2002</year><volume>2</volume><fpage>604</fpage><lpage>610</lpage></element-citation></ref><ref id="b51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowry</surname><given-names>NH</given-names></name><name><surname>Passonneau</surname><given-names>JV</given-names></name><name><surname>Rock</surname><given-names>MK</given-names></name></person-group><source>J Biol Chem</source><year>1961</year><volume>236</volume><fpage>2756</fpage><lpage>2759</lpage><pub-id pub-id-type="pmid">14466980</pub-id></element-citation></ref><ref id="b52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernofsky</surname><given-names>C</given-names></name></person-group><source>Arch Biochem Biophys</source><year>1975</year><volume>166</volume><fpage>645</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">235242</pub-id></element-citation></ref><ref id="b53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>JL</given-names></name><name><surname>Shapiro</surname><given-names>R</given-names></name></person-group><source>Biochemistry</source><year>2003</year><volume>42</volume><fpage>6674</fpage><lpage>6687</lpage><pub-id pub-id-type="pmid">12779322</pub-id></element-citation></ref><ref id="b54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otwinowski</surname><given-names>Z</given-names></name><name><surname>Minor</surname><given-names>W</given-names></name></person-group><source>Methods Enzymol</source><year>1997</year><volume>276</volume><fpage>307</fpage><lpage>326</lpage></element-citation></ref><ref id="b55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>S</given-names></name></person-group><source>Acta Crystallogr Sect D</source><year>1994</year><volume>50</volume><fpage>760</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">15299374</pub-id></element-citation></ref><ref id="b56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>French</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>K</given-names></name></person-group><source>Acta Crystallogr Sect A</source><year>1978</year><volume>34</volume><fpage>517</fpage><lpage>525</lpage></element-citation></ref><ref id="b57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navaza</surname><given-names>J</given-names></name></person-group><source>Acta Crystallogr Sect A</source><year>1994</year><volume>50</volume><fpage>157</fpage><lpage>163</lpage></element-citation></ref><ref id="b58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Br&#252;nger</surname><given-names>AT</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Clore</surname><given-names>GM</given-names></name><name><surname>DeLano</surname><given-names>WD</given-names></name><name><surname>Gros</surname><given-names>P</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>Jiang</surname><given-names>J-S</given-names></name><name><surname>Kuszewski</surname><given-names>J</given-names></name><name><surname>Nilges</surname><given-names>M</given-names></name><name><surname>Pannu</surname><given-names>NS</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Rice</surname><given-names>LM</given-names></name><name><surname>Simonson</surname><given-names>T</given-names></name><name><surname>Warren</surname><given-names>GL</given-names></name></person-group><source>Acta Crystallogr Sect D</source><year>1998</year><volume>54</volume><fpage>905</fpage><lpage>921</lpage><pub-id pub-id-type="pmid">9757107</pub-id></element-citation></ref><ref id="b59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>TA</given-names></name><name><surname>Zou</surname><given-names>J-Y</given-names></name><name><surname>Cowan</surname><given-names>SW</given-names></name><name><surname>Kjeldgaard</surname><given-names>M</given-names></name></person-group><source>Acta Crystallogr Sect D</source><year>1991</year><volume>A47</volume><fpage>110</fpage><lpage>119</lpage></element-citation></ref><ref id="b60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><source>Acta Crystallogr Sect D</source><year>2004</year><volume>60</volume><fpage>2126</fpage><lpage>2132</lpage><pub-id pub-id-type="pmid">15572765</pub-id></element-citation></ref><ref id="b61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krissinel</surname><given-names>EB</given-names></name><name><surname>Winn</surname><given-names>MD</given-names></name><name><surname>Ballard</surname><given-names>CC</given-names></name><name><surname>Ashton</surname><given-names>AW</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Potterton</surname><given-names>EA</given-names></name><name><surname>McNicholas</surname><given-names>SJ</given-names></name><name><surname>Cowtan</surname><given-names>KD</given-names></name><name><surname>Emsley</surname><given-names>P</given-names></name></person-group><source>Acta Crystallogr Sect D</source><year>2004</year><volume>60</volume><fpage>2250</fpage><lpage>2255</lpage><pub-id pub-id-type="pmid">15572778</pub-id></element-citation></ref><ref id="b62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaguine</surname><given-names>AA</given-names></name><name><surname>Richelle</surname><given-names>J</given-names></name><name><surname>Wodak</surname><given-names>SJ</given-names></name></person-group><source>Acta Crystallogr Sect D</source><year>1999</year><volume>55</volume><fpage>191</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">10089410</pub-id></element-citation></ref></ref-list></back></article>